FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022749609> ?p ?o ?g. }

• W2022749609 endingPage "131" @default.
• W2022749609 startingPage "123" @default.
• W2022749609 abstract "PurposeHigh sustained antibody titers complicate many disorders treated with a therapeutic protein, including those treated with enzyme replacement therapy, such as Pompe disease. Although enzyme replacement therapy with alglucosidase alfa (Myozyme) in Pompe disease has improved the prognosis of this otherwise lethal disorder, patients who develop high sustained antibody titers to alglucosidase alfa enter a prolonged phase of clinical decline resulting in death despite continued enzyme replacement therapy. Clinically effective immune-tolerance induction strategies have yet to be described in the setting of an entrenched immune response characterized by high sustained antibody titers, wherein antibody-producing plasma cells play an especially prominent role.MethodsWe treated three patients with infantile Pompe disease experiencing marked clinical decline due to high sustained antibody titers. To target the plasma cell source of high sustained antibody titers, a regimen based on bortezomib (Velcade) was used in combination with rituximab, methotrexate, and intravenous immunoglobulin.ResultsThe treatment regimen was well tolerated, with no obvious side effects. Patient 1 had a 2,048-fold, and patients 2 and 3 each had a 64-fold, reduction in anti-alglucosidase alfa antibody titer, with concomitant sustained clinical improvement.ConclusionThe addition of bortezomib to immunomodulatory regimens is an effective and safe treatment strategy in infantile Pompe disease, with potentially broader clinical implications.Genet Med 2013:15(2):123–131" @default.
• W2022749609 created "2016-06-24" @default.
• W2022749609 creator A5020301234 @default.
• W2022749609 creator A5028231831 @default.
• W2022749609 creator A5032065692 @default.
• W2022749609 creator A5037775852 @default.
• W2022749609 creator A5039716945 @default.
• W2022749609 creator A5040824471 @default.
• W2022749609 creator A5042754710 @default.
• W2022749609 creator A5047442341 @default.
• W2022749609 creator A5049485343 @default.
• W2022749609 creator A5063827456 @default.
• W2022749609 creator A5068208945 @default.
• W2022749609 creator A5082165037 @default.
• W2022749609 date "2013-02-01" @default.
• W2022749609 modified "2023-10-01" @default.
• W2022749609 title "Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease" @default.
• W2022749609 cites W1969555423 @default.
• W2022749609 cites W1970325263 @default.
• W2022749609 cites W1978337429 @default.
• W2022749609 cites W1984182083 @default.
• W2022749609 cites W2010024164 @default.
• W2022749609 cites W2012363247 @default.
• W2022749609 cites W2032340135 @default.
• W2022749609 cites W2037050042 @default.
• W2022749609 cites W2041769721 @default.
• W2022749609 cites W2055655054 @default.
• W2022749609 cites W2074051660 @default.
• W2022749609 cites W2076454500 @default.
• W2022749609 cites W2091668353 @default.
• W2022749609 cites W2091777991 @default.
• W2022749609 cites W2091858933 @default.
• W2022749609 cites W2092641711 @default.
• W2022749609 cites W2098837289 @default.
• W2022749609 cites W2099289539 @default.
• W2022749609 cites W2100199292 @default.
• W2022749609 cites W2100229044 @default.
• W2022749609 cites W2108235071 @default.
• W2022749609 cites W2118533061 @default.
• W2022749609 cites W2120547404 @default.
• W2022749609 cites W2127215106 @default.
• W2022749609 cites W2130528924 @default.
• W2022749609 cites W2133992969 @default.
• W2022749609 cites W2134392644 @default.
• W2022749609 cites W2143296077 @default.
• W2022749609 cites W2143609092 @default.
• W2022749609 cites W2144392873 @default.
• W2022749609 cites W2149662993 @default.
• W2022749609 cites W2152085236 @default.
• W2022749609 cites W2165068832 @default.
• W2022749609 cites W2339029146 @default.
• W2022749609 cites W298506661 @default.
• W2022749609 cites W1607180579 @default.
• W2022749609 doi "https://doi.org/10.1038/gim.2012.110" @default.
• W2022749609 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3744338" @default.
• W2022749609 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23060045" @default.
• W2022749609 hasPublicationYear "2013" @default.
• W2022749609 type Work @default.
• W2022749609 sameAs 2022749609 @default.
• W2022749609 citedByCount "69" @default.
• W2022749609 countsByYear W20227496092013 @default.
• W2022749609 countsByYear W20227496092014 @default.
• W2022749609 countsByYear W20227496092015 @default.
• W2022749609 countsByYear W20227496092016 @default.
• W2022749609 countsByYear W20227496092017 @default.
• W2022749609 countsByYear W20227496092018 @default.
• W2022749609 countsByYear W20227496092019 @default.
• W2022749609 countsByYear W20227496092020 @default.
• W2022749609 countsByYear W20227496092021 @default.
• W2022749609 countsByYear W20227496092022 @default.
• W2022749609 countsByYear W20227496092023 @default.
• W2022749609 crossrefType "journal-article" @default.
• W2022749609 hasAuthorship W2022749609A5020301234 @default.
• W2022749609 hasAuthorship W2022749609A5028231831 @default.
• W2022749609 hasAuthorship W2022749609A5032065692 @default.
• W2022749609 hasAuthorship W2022749609A5037775852 @default.
• W2022749609 hasAuthorship W2022749609A5039716945 @default.
• W2022749609 hasAuthorship W2022749609A5040824471 @default.
• W2022749609 hasAuthorship W2022749609A5042754710 @default.
• W2022749609 hasAuthorship W2022749609A5047442341 @default.
• W2022749609 hasAuthorship W2022749609A5049485343 @default.
• W2022749609 hasAuthorship W2022749609A5063827456 @default.
• W2022749609 hasAuthorship W2022749609A5068208945 @default.
• W2022749609 hasAuthorship W2022749609A5082165037 @default.
• W2022749609 hasBestOaLocation W20227496091 @default.
• W2022749609 hasConcept C126322002 @default.
• W2022749609 hasConcept C159654299 @default.
• W2022749609 hasConcept C203014093 @default.
• W2022749609 hasConcept C22889606 @default.
• W2022749609 hasConcept C2776364478 @default.
• W2022749609 hasConcept C2777478702 @default.
• W2022749609 hasConcept C2779134260 @default.
• W2022749609 hasConcept C2779384505 @default.
• W2022749609 hasConcept C2779969927 @default.
• W2022749609 hasConcept C2780653079 @default.
• W2022749609 hasConcept C2781413609 @default.
• W2022749609 hasConcept C32611913 @default.
• W2022749609 hasConcept C71924100 @default.

• next